

SHORT COMMUNICATIONS

Investigation of the alkylating action of 1,1-dimethylhydrazine

(Received 19 September 1969; accepted 13 November 1969)

THE CARCINOGENIC action of dimethylnitrosamine¹ has been correlated with the fact, that administration of this compound leads to the formation of 7-methylguanine in DNA and RNA of several tissues in rats.² According to Lijinsky *et al.*³ the formation of diazomethane as an alkylating intermediate must be excluded. 1,1-dimethylhydrazine is a possible metabolite of dimethylnitrosamine, for it has been shown by Süss,⁴ that *N*-nitrosomorpholine is metabolized to the corresponding hydrazine derivative by liver homogenates. 1,1-dimethylhydrazine is mutagenic⁵ and is carcinogenic in mice,⁶ but was found inactive⁸ or only weakly active⁷ in rats. We have tested whether ¹⁴C-1,1-dimethylhydrazine acts as alkylating agent on the RNA of liver and on the RNA of the Yoshida transplantation tumor in rats.

¹⁴C-1,1-dimethylhydrazine was synthesized from ¹⁴C-dimethylnitrosamine by reduction with zinc dust in acetic acid as described in Organic Synthesis.⁹

Male Sprague-Dawley rats (300–350 g) with solid growing Yoshida transplantation tumors of about 2–3 g were used. The animals were maintained at Altromin[®]-diet and water *ad lib*. Three rats were injected intravenously with 80 mg/45 μ Ci/kg ¹⁴C-1,1-dimethylhydrazine hydrochloride. Livers and tumors were removed 6 hr after application. The RNA was prepared by the modified method of Kidson, Kirby and Ralph^{10, 11} and was hydrolyzed for 1 hr with 1 N HCl. The hydrolysate was chromatographed on a Dowex-column (WX 2 (H⁺)) using a 1–3 N HCl gradient.

The RNA of the liver showed little incorporation of radioactivity whereas the RNA of the tumor was labelled. In both cases the labelling was due to the biological incorporation of the radioactivity into the purine bases. No 7-methylguanine was detected. It therefore must be concluded that even if 1,1-dimethylhydrazine is formed from dimethylnitrosamine, this compound is not an alkylating intermediate.

Acknowledgement—This work has been made possible by the Deutschen Forschungsgemeinschaft. The authors thank Mrs. I. Reinig and Mr. H. Braun for skilled technical assistance.

*Institut für experimentelle Toxikologie und Chemotherapie
am Deutschen Krebsforschungszentrum
Heidelberg, Germany*

F. W. KRÜGER
M. WIESSLER
U. RÜCKER

REFERENCES

1. P. N. MAGEE and J. M. BARNES, *Br. J. Cancer* **10**, 114 (1956).
2. P. N. MAGEE and E. FABER, *Biochem. J.* **83**, 114 (1962).
3. W. LIJINSKY, J. LOO and A. E. ROSS, *Nature* **218**, 1174 (1968).
4. R. SÜSS, *Z. Naturforsch.* **20b**, 714 (1965).
5. F. LINGENS, *Z. Naturforsch.* **19b**, 151 (1964).
6. F. C. J. ROE, G. A. GRANT and D. M. MILLICAN, *Nature, Lond.* **216**, 376 (1967).
7. H. DRUCKREY, R. PREUSSMANN, S. IVANKIVIC and D. SCHMÄHL, *Z. Krebsforsch.* **69**, 103 (1967).
8. M. F. ARGUS and C. HOCH-LIGETI, *J. Nat. Cancer Inst.* **27**, 695 (1961).
9. Organic Synthesis XVI, 22 (1936).
10. C. KIDSON, K. S. KIRBY and R. K. RALPH, *J. molec. Biol.* **7**, 312 (1963).
11. P. F. SWANN and P. N. MAGEE, *Biochem. J.* **110**, 39 (1968).